{"log_id": 3230525466503369483, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.00485, "average": 0.928677, "min": 0.859037}, "location": {"width": 42, "top": 76, "height": 97, "left": 1137}, "words": "首文"}, {"probability": {"variance": 0.006497, "average": 0.981218, "min": 0.542962}, "location": {"width": 717, "top": 232, "height": 30, "left": 258}, "words": "在试验方案规定的分析中,出现与阿巴卡韦/恩曲他滨/拉米夫定耐药相关的"}, {"probability": {"variance": 0.002346, "average": 0.981367, "min": 0.734344}, "location": {"width": 820, "top": 277, "height": 30, "left": 219}, "words": "M184V突变的HIV-1受试者对富马酸替诺福韦二吡呋酯的病毒学应答没有降低。这些"}, {"probability": {"variance": 0.000236, "average": 0.993653, "min": 0.926506}, "location": {"width": 459, "top": 322, "height": 29, "left": 214}, "words": "患者中HIV-1RNA反应在第48周期间持续存在"}, {"probability": {"variance": 0.003634, "average": 0.984693, "min": 0.639349}, "location": {"width": 769, "top": 365, "height": 29, "left": 258}, "words": "研究902和907表型分析:接受过治疗的受试者(N=100)基线HIV-1表型分析"}, {"probability": {"variance": 1.2e-05, "average": 0.998582, "min": 0.979583}, "location": {"width": 811, "top": 409, "height": 28, "left": 218}, "words": "表明,基线病毒对富马酸替诺福韦二吡呋酯的敏感性和患者对富马酸替诺福韦二吡呋"}, {"probability": {"variance": 1.2e-05, "average": 0.997996, "min": 0.980864}, "location": {"width": 807, "top": 454, "height": 29, "left": 215}, "words": "酯治疗的应答之间存在相关性。表14按照基线富马酸替诺福韦二吡呋酯的敏感性总"}, {"probability": {"variance": 0.011802, "average": 0.955385, "min": 0.59674}, "location": {"width": 232, "top": 498, "height": 27, "left": 215}, "words": "结了HIV-1RNA的应答"}, {"probability": {"variance": 0.004801, "average": 0.981804, "min": 0.543572}, "location": {"width": 812, "top": 645, "height": 26, "left": 216}, "words": "表14第24周时HIV-1RNA的应答,根据基线富马酸替诺福韦二吡呋酯的敏感性分组(意向"}, {"probability": {"variance": 0.000607, "average": 0.972081, "min": 0.939888}, "location": {"width": 50, "top": 684, "height": 23, "left": 218}, "words": "治疗)"}, {"probability": {"variance": 0.013748, "average": 0.967177, "min": 0.49863}, "location": {"width": 314, "top": 722, "height": 24, "left": 250}, "words": "基线富马酸替诺福韦二吡呋酯的敏感性"}, {"probability": {"variance": 0.00108, "average": 0.972723, "min": 0.902333}, "location": {"width": 196, "top": 724, "height": 22, "left": 693}, "words": "HIV-1RNA的变化3(N"}, {"probability": {"variance": 0.00023, "average": 0.983971, "min": 0.968808}, "location": {"width": 21, "top": 766, "height": 18, "left": 404}, "words": "<1"}, {"probability": {"variance": 0.000212, "average": 0.989915, "min": 0.955702}, "location": {"width": 82, "top": 762, "height": 21, "left": 754}, "words": "0.74(35"}, {"probability": {"variance": 0.000192, "average": 0.989099, "min": 0.961937}, "location": {"width": 63, "top": 798, "height": 21, "left": 382}, "words": ">1且≤3"}, {"probability": {"variance": 0.019721, "average": 0.939276, "min": 0.595412}, "location": {"width": 86, "top": 799, "height": 20, "left": 755}, "words": "0.56(49"}, {"probability": {"variance": 0.000276, "average": 0.98077, "min": 0.951533}, "location": {"width": 62, "top": 834, "height": 22, "left": 383}, "words": ">3且≤4"}, {"probability": {"variance": 9.9e-05, "average": 0.990354, "min": 0.969515}, "location": {"width": 71, "top": 834, "height": 20, "left": 763}, "words": "0.3(7)"}, {"probability": {"variance": 0.001388, "average": 0.97564, "min": 0.890813}, "location": {"width": 238, "top": 905, "height": 22, "left": 249}, "words": "使用重组表型 Antivirogram检验"}, {"probability": {"variance": 1.7e-05, "average": 0.99786, "min": 0.987046}, "location": {"width": 162, "top": 905, "height": 22, "left": 565}, "words": "测定替诺韦的敏感性"}, {"probability": {"variance": 4e-06, "average": 0.998508, "min": 0.993225}, "location": {"width": 279, "top": 938, "height": 21, "left": 251}, "words": "相对于野生型耐药株敏感性的改变倍数"}, {"probability": {"variance": 0.00145, "average": 0.768856, "min": 0.730775}, "location": {"width": 100, "top": 930, "height": 41, "left": 886}, "words": "(中"}, {"probability": {"variance": 0.009579, "average": 0.969506, "min": 0.477897}, "location": {"width": 399, "top": 970, "height": 24, "left": 251}, "words": "在第24周期间HIV1RNA相对于基线值的平均变化(D"}, {"probability": {"variance": 0.006068, "average": 0.956041, "min": 0.75898}, "location": {"width": 152, "top": 971, "height": 21, "left": 734}, "words": "单位为log10拷贝/ml"}, {"probability": {"variance": 0.000342, "average": 0.989847, "min": 0.948634}, "location": {"width": 115, "top": 1004, "height": 26, "left": 258}, "words": "抗HBV活性"}, {"probability": {"variance": 7.9e-05, "average": 0.996516, "min": 0.94819}, "location": {"width": 782, "top": 1045, "height": 28, "left": 259}, "words": "抗病毒活性:在HepG22.2.15细胞系中对替诺福韦抗HBV的抗病毒活性进行评估"}, {"probability": {"variance": 0.016638, "average": 0.946028, "min": 0.363471}, "location": {"width": 818, "top": 1087, "height": 31, "left": 217}, "words": "替诺福韦的ECs值在0.14~1.5μM之间,CC(50%细胞毒性浓度)值大于100μM。在"}, {"probability": {"variance": 0.000183, "average": 0.994455, "min": 0.928586}, "location": {"width": 812, "top": 1130, "height": 27, "left": 218}, "words": "细胞培养中研究替诺福韦与核苷类HBV逆转录酶抑制剂恩替卡韦、拉米夫定和替比夫"}, {"probability": {"variance": 0.000413, "average": 0.994755, "min": 0.875336}, "location": {"width": 812, "top": 1171, "height": 28, "left": 218}, "words": "定,以及与核苷类HIV-1逆转录酶抑制剂恩曲他滨联合用药的抗病毒活性,未观察到"}, {"probability": {"variance": 2.9e-05, "average": 0.996925, "min": 0.98502}, "location": {"width": 131, "top": 1215, "height": 26, "left": 219}, "words": "任何拮抗作用"}, {"probability": {"variance": 0.003078, "average": 0.987831, "min": 0.606162}, "location": {"width": 783, "top": 1256, "height": 27, "left": 260}, "words": "耐药性:对于研究0102、0103、0106、0108、0121和LOC114648中接受富马酸替"}, {"probability": {"variance": 0.000181, "average": 0.995222, "min": 0.927396}, "location": {"width": 823, "top": 1298, "height": 28, "left": 219}, "words": "诺福韦二吡呋酯单药治疗至少24周但在每研究年末时(或终止富马酸替诺福韦二吡呋"}, {"probability": {"variance": 1e-05, "average": 0.99822, "min": 0.985424}, "location": {"width": 849, "top": 1339, "height": 30, "left": 218}, "words": "酯单药治疗时)病毒血症 HBV DNA仍大于或等于400拷贝/毫升的受试者,用其治疗前"}, {"probability": {"variance": 0.00255, "average": 0.989711, "min": 0.683291}, "location": {"width": 816, "top": 1383, "height": 29, "left": 218}, "words": "和治疗期间配对的分离HBV逆转录酶氨基酸序列(部分或全段序列)样本进行每年一"}], "language": 3}